 BERKELEY, Calif., March 07, 2022 GLOBE NEWSWIRE -- Caribou Biosciences, Inc. Nasdaq: CRBU, a leading clinical-stage CRISPR genome-editing biopharmaceutical company, announced today that Rachel Haurwitz, Ph.D., Caribous president and chief executive officer, will present a company overview at the following upcoming investor conferences in March: 